Clinical Characteristics and Molecular Patterns of -Rearranged Lung Cancer in Chinese Patients.

rearrangement has been proven as an oncogenic driver in patients with lung cancer. However, the prevalence, clinical characteristics, molecular features, and therapeutic options in -rearranged patients remain unclear, especially in Chinese lung cancer patients. We retrospectively collected 6,125 Chinese lung cancer patients who have been profiled using next-generation sequencing (NGS). The clinical demographics and molecular features of rearrangement-positive patients were analyzed. rearrangements were identified in 84 patients with a proportion of 1.4% in our cohort. The median age at diagnosis was 58 years, and it mainly occurred in females with adenocarcinoma histology. was the most frequent fusion type and accounted for 53.8% (57/106) of all fusions identified, with K15-R12 as the most frequent variant (71.9%). Among 47 patients profiled with larger panels, 72.3% (34/47) harbored concurrent alterations. ranked as the most common concurrent alteration, and concomitant oncogenic alterations were identified in seven patients. Moreover, an adenocarcinoma patient harboring concurrent fusion and L858R responded to combinatorial treatment of cabozantinib and osimertinib, with a progression-free survival of 5 months. Our study improved knowledge of clinical characteristics and molecular features of -rearranged lung cancers in China. It might be helpful to guide clinicians for more effective personalized diagnostic and therapeutic approaches.